QUOTE AND NEWS
StreetInsider.com  9 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29%2C+Sanofi+%28SNY%29+Close+Global+Development%2C+Commercialization+Agreement+for+Afrezza/9858905.html for the full story.
Motley Fool  Sep 24  Comment 
MannKind is a stock with tremendous promise -- and tremendous peril.
StreetInsider.com  Sep 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi%27s+%28SNY%29+Genzyme+Enter+Research+Collaboration+Covering+LCA-1/9856883.html for the full story.
Benzinga  Sep 24  Comment 
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic...
Benzinga  Sep 23  Comment 
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the introduction of Oxaliplatin Injection, USP, an antineoplastic agent, now in two liquid presentations. According to IMS, for the 12 months ending July 2014, the US market for...
SeekingAlpha  Sep 21  Comment 
By Apex Financial Consultants: Sanofi SA (NYSE:SNY) is all set to make dengue a vaccine-preventable disease after 20 years of research and industrial commitment. In clinical trials the company's experimental vaccine protected children from all...
MedPage Today  Sep 19  Comment 
VIENNA (MedPage Today) -- Insulin glargine (Lantus) continued to carry no increased risk of cardiovascular events compared with standard care in an extension of the ORIGIN trial, researchers reported here.
Forbes  Sep 18  Comment 
Big Pharma’s onward race to tap biotech ingenuity in the face of its traditional and problematic large-scale R&D model has spurred new kinds of early-stage collaborations, ranging from Johnson & Johnson’s Innovation Centers to Pfizer’s...
FierceBiotech  Sep 18  Comment 
A little more than two months after inking a licensing deal with Sanofi, CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also...
SeekingAlpha  Sep 17  Comment 
By Investing Tricks: Sanofi's (NYSE:SNY) revenues are distributed through three major segments and a large chunk is attributable to the pharmaceutical segment; 85% of revenues are attributed to the pharmaceutical segment. More than half the...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki